Literature DB >> 16821112

Sulforaphane induces inhibition of human umbilical vein endothelial cells proliferation by apoptosis.

Masahiro Asakage1, Nelson H Tsuno, Joji Kitayama, Takeshi Tsuchiya, Satomi Yoneyama, Jun Yamada, Yurai Okaji, Shoichi Kaisaki, Takuya Osada, Koki Takahashi, Hirokazu Nagawa.   

Abstract

Sulforaphane (SUL), one of the isothiocyanates (ITCs), has recently been focused due to its inhibitory effects on tumor cell growth in vitro and in vivo, which is dependent on the direct effect on cancer cells. In the present study, we aimed to investigate the potential anti-angiogenic effect of SUL and its mechanism of action. Using the human umbilical vein endothelial cells (HUVECs) as a model of angiogenesis, we investigated the effect of SUL on the various steps of angiogenesis, including the proliferation of endothelial cells, tubular formation, and matrix metalloproteinase (MMP) production. Sulforaphane induced a dose-dependent decrease in the proliferative activity of endothelial cells, which was dependent on cell apoptosis. Also SUL inhibited tube formation on matrigel, but did not affect MMP production. The present results demonstrate the anti-angiogenic activity of SUL and its potential use as an anti-cancer drug is suggested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16821112     DOI: 10.1007/s10456-006-9034-0

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  18 in total

1.  Sulforaphane as a Promising Natural Molecule for Cancer Prevention and Treatment.

Authors:  Osama A Elkashty; Simon D Tran
Journal:  Curr Med Sci       Date:  2021-04-20

2.  Discovery of novel sulfonated small molecules that inhibit vascular tube formation.

Authors:  Karthik Raman; Rajesh Karuturi; Vimal P Swarup; Umesh R Desai; Balagurunathan Kuberan
Journal:  Bioorg Med Chem Lett       Date:  2012-04-16       Impact factor: 2.823

3.  Characterization of the threshold for NAD(P)H:quinone oxidoreductase activity in intact sulforaphane-treated pulmonary arterial endothelial cells.

Authors:  Robert D Bongard; Gary S Krenz; Adam J Gastonguay; Carol L Williams; Brian J Lindemer; Marilyn P Merker
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

Review 4.  Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention.

Authors:  Besma Abbaoui; Christopher R Lucas; Ken M Riedl; Steven K Clinton; Amir Mortazavi
Journal:  Mol Nutr Food Res       Date:  2018-08-29       Impact factor: 5.914

5.  Development and in vitro assessment of enzymatically-responsive poly(ethylene glycol) hydrogels for the delivery of therapeutic peptides.

Authors:  Amy H Van Hove; Michael-John G Beltejar; Danielle S W Benoit
Journal:  Biomaterials       Date:  2014-08-30       Impact factor: 12.479

Review 6.  Role of 4-hydroxynonenal in chemopreventive activities of sulforaphane.

Authors:  Rajendra Sharma; Abha Sharma; Pankaj Chaudhary; Mukesh Sahu; Shailesh Jaiswal; Sanjay Awasthi; Yogesh C Awasthi
Journal:  Free Radic Biol Med       Date:  2012-04-23       Impact factor: 7.376

7.  Tumor angiogenesis as a target for dietary cancer prevention.

Authors:  William W Li; Vincent W Li; Michelle Hutnik; Albert S Chiou
Journal:  J Oncol       Date:  2011-09-29       Impact factor: 4.375

8.  Development of a High-Fibre Multigrain Bar Technology with the Addition of Curly Kale.

Authors:  Hanna Kowalska; Jolanta Kowalska; Anna Ignaczak; Ewelina Masiarz; Ewa Domian; Sabina Galus; Agnieszka Ciurzyńska; Agnieszka Salamon; Agnieszka Zając; Agata Marzec
Journal:  Molecules       Date:  2021-06-28       Impact factor: 4.411

9.  The influence of sulforaphane on vascular health and its relevance to nutritional approaches to prevent cardiovascular disease.

Authors:  Paul C Evans
Journal:  EPMA J       Date:  2011-02-12       Impact factor: 6.543

10.  Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo.

Authors:  Jin-Mu Yi; Jong-Shik Park; Se-Mi Oh; Jun Lee; Jinhee Kim; Dal-Seok Oh; Ok-Sun Bang; No Soo Kim
Journal:  BMC Complement Altern Med       Date:  2012-12-04       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.